Acuta Capital Partners, LLC Cardiff Oncology, Inc. Transaction History

Acuta Capital Partners, LLC

  • $70.3 Million
  • Q4 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021
SELL
$12.02 - $24.71 $3.68 Million - $7.56 Million
-305,900 Closed
0 $0
Q3 2020

Nov 16, 2020
SELL
$4.25 - $14.19 $431,800 - $1.44 Million
-101,600 Reduced 24.93%
305,900 $4.34 Million
Q2 2020

Aug 14, 2020
BUY
$0.78 - $5.1 $317,850 - $2.08 Million
407,500 New
407,500 $2.04 Million

Others Institutions Holding CRDF

# of Institutions
114
Shares Held
16.2M
Call Options Held
694K
Put Options Held
140K
View Full List

About Cardiff Oncology, Inc.

CRDF Quotes by TradingView
  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $186M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Acuta Capital Partners, LLC Portfolio

Follow Acuta Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acuta Capital Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email